SATB2 Antibody (DA210)

Description

Special AT-rich sequence-binding protein 2 (SATB2) is a marker that functions as a nuclear matrix-associated transcription factor that has been shown to identify colorectal carcinomas, including poorly differentiated colorectal carcinomas and metastases.1,2,3 Adenocarcinomas including breast, lung, and ovary may express SATB2 at lower frequencies.1,2,3,4,5 Therefore, SATB2 is useful for identifying a carcinoma of colorectal origin when identifying a cancer of unknown primary.1,2 — Références — 1. Magnusson K, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011; 35:937-48. 2. Dragomir A, et al. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study. Am J Clin Pathol. 2014; 141:630-8. 3. Moh M, et al. SATB2 expression distinguishes ovarian metastases of colorectal and appendiceal origin from primary ovarian tumors of mucinous or endometrioid type. Am J Surg Pathol. 2016; 40:419-32. 4. Zhang YJ, et al. SATB2 is a promising biomarker for identifying a colorectal origin for liver metastatic adenocarcinomas. EBioMedicine. 2018; 28:62-69. 5. Brettfeld, Stefan M et al. "SATB2 Versus CDX2: A Battle Royale for Diagnostic Supremacy in Mucinous Tumors." Archives of pathology & laboratory medicine vol. 143,9 (2019): 1119-1125.

Caractéristiques

Type

Recombinant monoclonal rabbit antibody

Clone

DA210

Isotype

Rabbit

Réactivité

Synthetic peptide from human SATB2

Localisation

Nucleus

Usage prévu

IHC (FFPE)